Draft, not yet released. In stewardship review. Not indexed until the first approved release.

Synthetic biology is a build capability and a governance test

Part I describes systems and their couplings. It ranks no country or operator and assesses no authority.

7 min read2 figures1 table17 notesNR-XTECH-SYNBIO-GLOBAL-2026-BASELINE

Contents
  1. ·Edition home
  2. ·Executive summary
  3. 1Synthetic biology is a build capability and a governance test
    1. 1.1 The questions this part answers
    2. 1.2 The argument
    3. 1.3 Twenty couplings between five systems
  4. 2Key findings
  5. 3Systems and sectors at baseline
  6. 4Risks and capability
  7. 5Design capability outpaces screening and oversight
  8. 6Readings from the other desks
  9. 7The 2027 agenda
  10. 8Systems in depth
  11. AMethodology
  12. BData appendix
  13. CReferences and record
  14. ·Complete edition, for print

1.1The questions this part answers

Key questions

  • Where is synthetic biology risk concentrated?
  • Which couplings carry synthetic biology shocks into other systems?
  • Which synthetic biology capabilities hold under compound stress?
  • What must 2027 evidence measure first?

In this part

  • Narrative
  • Headline finding
  • Lead figure
  • Five footprint and governance chapters
  • Twelve-domain reading
  • Sector screens
  • Dependency matrix
  • Risk objects
  • Capability ladder
  • Scenario
  • Three lenses
  • Portfolio

1.2The argument

Synthetic biology is usually told as a story of products. The 2026 evidence reads it as three things at once: a capability to design and write living systems, a manufacturing base that needs DNA, instruments, feedstock and people, and a governance test for oversight that was written for slower tools11318.

The build evidence is strong at small scale. A bacterium now runs on a 57-codon genetic code, and a yeast strain carries six and a half synthetic chromosomes24. Software built 60 genetic circuits and 45 worked in every output state6. These are results on single organisms, not industrial platforms.

The risk evidence is newer and sharper. A 2025 study found that screening tools often missed protein variants redesigned with open software, and patches improved detection13. A 2024 policy forum asked for broad discussion of mirror life12. Governance is moving: a US commission report, an EU proposal and OECD and CBD work all appeared between 2022 and 2026, but implementation is uneven14182022.

The physical base is the least measured part. Company revenue is mixed, with Ginkgo Bioworks down and Twist Bioscience guiding up1617. Energy, water, feedstock, capacity and workforce figures are not published on a common basis.

Figure 1.1How much recoding has been built? Codons changed in a synthetic genome, thousands

The number of recoded codons rose about fivefold between two strains from the same research line. The Syn57 figure is stated as over 101,000, so the ratio is a lower bound23.

ItemBar, scaled to the largest valueValue
Syn61 strain, 2019: 18,214 codons18.2
Syn57 strain, 2025: over 101,000 codons101

Source: as cited in the note to this figure. Year 2025.

Figure ID FIG-XTECH-SYNBIO-GLOBAL-2026-BASELINE-01-003

101thousand codons

recoded in Syn57, lower bound2

18.2thousand codons

recoded in Syn613

38fragments

of about 100,000 base pairs each2

4million base pairs

approximate genome size1

1.3Twenty couplings between five systems

The synthetic biology-centred matrix types the twenty couplings between the five core systems, read for their synthetic biology content. Strengths are Nexus estimates (ESTIMATED) from the cited evidence and analogue events; they set the graph that 2027 evidence will test.

Figure 1.2Couplings between the five systems

Each line is one coupling from one system to another, drawn by the strength the edition assigns. Strengths are Nexus estimates from the cited evidence and analogue events.

  • Strong
  • Moderate
  • Weak

Source: this edition’s coupling matrix (Table 1.1); status Estimated.

Table 1.1Coupling matrix: from the row system to the column system
From, toWATENEFOOHLTBIO
WAT Water·WEAK
no documented link		WEAK
process water, undocumented		WEAK
no documented link		WEAK
process water, undocumented
ENE EnergyWEAK
no documented link		·WEAK
feedstock energy, undocumented		WEAK
no documented link		WEAK
process energy, undocumented
FOO FoodWEAK
no documented link		WEAK
no documented link		·WEAK
no documented link		WEAK
feedstock supply, undocumented
HLT HealthWEAK
no documented link		WEAK
no documented link		WEAK
no documented link		·WEAK
clinical demand, undocumented
BIO BiodiversityWEAK
no documented link		WEAK
bio-based fuels, undocumented		WEAK
no documented link		MODERATE
engineered cell therapies reach patients		·
Strength: strong, moderate or weak; a Nexus estimate (status Estimated) from cited evidence and analogue events. The scale is defined in Annex A.

Transmission paths

  1. 01

    DAT → BIO → SEC

    Design tools and sequence data lower the barrier to misuse faster than screening adapts.

    Reported 2025 screening study13

  2. 02

    BIO → HLT

    Engineered cell therapies move from research to patients.

    Reported exa-cel trial and regulator announcement89

  3. 03

    FIN → INF

    Public programmes fund manufacturing planning.

    Reported US programme awards2324

  4. 04

    ENE → BIO

    Process energy and feedstock constrain manufacturing at scale.

    Inferred no figure bound

  5. 05

    GOV → BIO

    Frameworks and proposals set oversight and incentives.

    Reported US, EU and OECD documents141822

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

  1. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
  2. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
  3. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
  4. 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.back
  5. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
  6. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back
  7. 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.back
  8. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
  9. 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.back
  10. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
  11. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
  12. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
  13. 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
  14. 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
  15. 9US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
  16. 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.back
  17. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back

Cite this chapter

Valadbaygi, S. (Ed.). (2026). Chapter 1: Synthetic biology is a build capability and a governance test. In Exponential Technology Report 2026: Synthetic Biology and Bioengineering (Baseline Edition 2026, Report No. NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI).

Every citation form of the whole report, BibTeX and RIS included, is on the edition home. Cite this report

ReportsContribute

Send evidence or a correction on Synthetic Biology and Bioengineering.

Reports is the Consortium’s quarterly publication, written by six desks. This page sits with the Global Centre for Risk and Innovation (GCRI) Systems Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.

GCRI Systems Evidence deskExponential Technology

Never send personal data, sensitive infrastructure detail or anything you have no right to share. A contribution is reviewed before use; sending it confers no authorship or editorial rights, and sponsorship never buys a finding.

CC BY 4.0 Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.

The Global Centre for Risk and Innovation

Science · evidence · measurement

Not for profit

Our articles, maps and twins are free to read and free to republish. Readers and partners keep it that way.

Partner with us

Who funds us

GCRI is a not-for-profit institution. To ask who funds a piece of work, use the funding questions form.

Independence

Editors and the expert reviewers named on each article decide what we publish. Funders and partners do not review or approve articles before publication.

Corrections policy

Licence

Articles: CC BY 4.0. Figures, maps, twins and data: CC BY 4.0. Other uses: ask through the permissions form.

Privacy choices